Caris Life Sciences, Inc. Common Stock (CAI) is a publicly traded Healthcare sector company. As of May 21, 2026, CAI trades at $15.73 with a market cap of $4.27B and a P/E ratio of -2.47. CAI moved +4.88% today. Year to date, CAI is -40.55%; over the trailing twelve months it is flat. Its 52-week range spans $14.19 to $42.50. Analyst consensus is strong buy with an average price target of $27.92. Rallies surfaces CAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Caris Lookback Program Flags 13,293 Patients for 87 New Targeted Therapies: Caris's Lookback Program retrospectively analyzed more than 483,000 molecular profiles to flag 13,293 patients now eligible for 87 new biomarker-directed FDA approvals across ten tumor types, with non-small cell lung cancer accounting for 40% of identified cases. MI Cancer Seek's combined WES/WTS assay extends clinical actionability without repeat biopsies.
| Metric | Value |
|---|---|
| Price | $15.73 |
| Market Cap | $4.27B |
| P/E Ratio | -2.47 |
| EPS | $-6.27 |
| Dividend Yield | 0.30% |
| 52-Week High | $42.50 |
| 52-Week Low | $14.19 |
| Volume | 2.50M |
| Avg Volume | 0 |
| Revenue (TTM) | $907.29M |
| Net Income | $33.98M |
| Gross Margin | 0.00% |
12 analysts cover CAI: 0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.92.